These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical trials of neuroprotection for Parkinson's disease. LeWitt PA Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583 [No Abstract] [Full Text] [Related]
3. Neuroprotection by selegiline and other MAO inhibitors. Stern G J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613 [TBL] [Abstract][Full Text] [Related]
4. Reexamination of the TEMPO Study. Shults CW Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778 [No Abstract] [Full Text] [Related]
5. Neuroprotective actions of selegiline. Ebadi M; Sharma S; Shavali S; El Refaey H J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232 [TBL] [Abstract][Full Text] [Related]
6. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Jenner P Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581 [No Abstract] [Full Text] [Related]
7. Selegiline in Parkinson's disease. Calne DB BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790 [No Abstract] [Full Text] [Related]
8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
10. Preclinical versus clinical neuroprotection. Grünblatt E; Schlösser R; Gerlach M; Riederer P Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689 [No Abstract] [Full Text] [Related]
11. [What strategies are recommended for early stage disease? Other treatments]. Damier P Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():105-8. PubMed ID: 10916044 [No Abstract] [Full Text] [Related]
12. Selegiline for Parkinson's disease. Calesnick B Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624 [TBL] [Abstract][Full Text] [Related]
13. Deprenyl--past and future. Proceedings of a symposium. Lake Starnberg, Bavaria, 1995. J Neural Transm Suppl; 1996; 48():1-112. PubMed ID: 9102455 [No Abstract] [Full Text] [Related]
14. [Drug therapy of Parkinson's disease]. Myllylä V Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076 [No Abstract] [Full Text] [Related]
15. DATATOP-study: significance of its results in the treatment of Parkinson's disease. Schneider E J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074 [TBL] [Abstract][Full Text] [Related]
16. [Use of iumeks in the combined therapy of parkinsonism patients ]. Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415 [No Abstract] [Full Text] [Related]
17. Free-radical toxicity and antioxidant medications in Parkinson's disease. Ciccone CD Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976 [No Abstract] [Full Text] [Related]
18. The fabulous neuroprotection of selegiline: memoir and prospectus. Landau WM J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135 [No Abstract] [Full Text] [Related]
19. MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138 [No Abstract] [Full Text] [Related]